6 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 6 |
| Phase 1 | 1 | Terminated 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010) - Hematologic Malignancy | Phase 2 | Terminated | Prolacta Bioscience | 46 | 2023-09-18 | 2024-08-19 |
| Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG) - Hematologic Malignancy, Myeloid Malignancy | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2023-03-14 | 2025-10-02 |
| Thrombosomes® in Bleeding Thrombocytopenic Patients Study Thrombosomes, Liquid Stored Platelets (LSP) - Thrombocytopenia, Hematologic Malignancy | Phase 2 | Terminated | Cellphire Therapeutics, Inc. | 21 | 2021-03-05 | 2023-05-25 |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies ClinicMACs - Hematologic Malignancy | Phase 2 | Terminated | Dana-Farber Cancer Institute | 2 | 2020-01-21 | 2022-05-10 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| Voraxaze for Delayed Methotrexate Clearance Voraxaze (Glucarpidase), Placebo - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2007-01-01 | 2012-12-06 |
Hematologic Neoplasms (6) · Anemia, Aplastic (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Neoplasms, Plasma Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Thrombocytopenia (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Immune System Diseases (2) · Anemia (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Chronic Disease (1) · Cytopenia (1) · Disease Attributes (1) · Immunoproliferative Disorders (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1)
Cyclophosphamide (2) · Radiotherapy (2) · Whole-Body Irradiation (2) · Antilymphocyte Serum (1) · Busulfan (1) · Cyclosporine (1) · Cyclosporins (1) · Health Maintenance Organizations (1) · Mesna (1) · Methotrexate (1) · Mycophenolic Acid (1) · Stem Cell Transplantation (1) · Tacrolimus (1) · Thiotepa (1) · fludarabine (1)
Cellphire Therapeutics, Inc. (1) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1) · Prolacta Bioscience (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · St. Jude Children's Research Hospital (1)
United States (6) · Israel (1) · Norway (1)
Ashok Srinivasan, MD (1) · Dolores Grosso, DNP, CRNP (1) · Mike Fitzpatrick, PhD (1) · Neal Flomenberg, MD (1) · Saroj Vadhan-Raj, MD (1) · Terry Gernsheimer, MD (1) · Vincent T Ho, MD (1)